Defibrotide

Drug Profile

Defibrotide

Alternative Names: Defibrotide sodium; Defitelio; Fraction P; JZP-381; Noravid; NS 73; Prociclide

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator Gentium
  • Developer Fukushima Medical University; Gentium; Jazz Pharmaceuticals plc; Swedish Orphan Biovitrum
  • Class Antithrombotics; Nucleotide aptamers; Polydeoxyribonucleotides
  • Mechanism of Action Angiogenesis inhibitors; Heparanase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Veno-occlusive disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Veno-occlusive disorders
  • Preclinical Diabetic nephropathies; Graft-versus-host disease
  • Market Withdrawal Deep vein thrombosis; Thrombosis
  • No development reported Multiple myeloma

Most Recent Events

  • 30 Mar 2017 Jazz Pharmaceuticals and Nippon Shinyaku agree to co-promote and co-develop defibrotide in Japan for Veno-occlusive disorders
  • 06 Feb 2017 Fukushima Medical University Hospital completes a phase II trial in Veno-occlusive disorders in Japan (UMIN000013454)
  • 02 Feb 2017 Adverse events and efficacy data from a subgroup analysis of an expanded access programme in Veno-occlusive disorders presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top